

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4859311

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CATHERINE OVERED-SAYER	03/30/2016
RECEIVING PARTY DATA	
Name:	MEDIMMUNE LIMITED
Street Address:	MILSTEIN BUILDING
Internal Address:	GRANTA PARK
City:	CAMBRIDGE
State/Country:	UNITED KINGDOM
Postal Code:	CB21 6GH
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15562228
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	patents@astrazeneca.com
Correspondent Name:	ASTRAZENECA/MEDIMMUNE
Address Line 1:	ONE MEDIMMUNE WAY
Address Line 4:	GAITHERSBURG, MARYLAND 20878
ATTORNEY DOCKET NUMBER:	IL33-105-US-NP
NAME OF SUBMITTER:	DENISE ADAMS
SIGNATURE:	/ADAMSD/
DATE SIGNED:	03/09/2018
Total Attachments: 3	
source=IL33-105-WO-PCT_OVERED-SAYER_Executed Assignment#page1.tif	
source=IL33-105-WO-PCT_OVERED-SAYER_Executed Assignment#page2.tif	
source=IL33-105-WO-PCT_OVERED-SAYER_Executed Assignment#page3.tif	

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 30th March 2016 (the "Effective Date") by and between

COHEN, Emma, S, LOWE, David, C, BUTLER, Robin, SCOTT, Ian, C, VOUSDEN, Katherine, A, STRAIN, Martin, D, CARMEN, Sara, ENGLAND, Elizabeth, H, KEMP, Benjamin, P, REES, David, G, OVERED-SAYER, Catherine, L, SLEEMAN, Matthew, HOUSLAY, Kirsty, all British citizens, all of MedImmune Limited, Milstein Building, Granta Park, Cambridge CB21 6GH United Kingdom ("Assignors"); and

MEDIMMUNE LIMITED, a company incorporated in England and Wales whose registered office is Milstein Building, Granta Park, Cambridge CB21 6GH United Kingdom ("Assignee")

WHEREAS

- A. Assignors have made certain inventions (the "Inventions") in respect of which the patent applications identified in the attached Schedule have been filed (the "Applications").
- B. Assignee wishes to secure the entire right, title and interest in and to the Inventions and to the Application.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. In consideration of payments made by Assignee to Assignors, receipt of which is hereby acknowledged, the Assignors hereby confirm that they have assigned, and in so far as there may be any outstanding rights that have not been assigned to the Assignee do hereby assign, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely all their right, title and interest in and to the Inventions, the Application and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Application and any patents or applications derived therefrom; and the right to file patent applications derived from the Application directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the "Rights"), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignors warrant that the Rights are unencumbered. Assignors acknowledge that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignors waive any right of first refusal that they may have for acquiring such Rights.
2. Assignors each hereby agree with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignors each hereby agree with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.

4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the English courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

COHEN, Emma, S

LOWE, David, C

BUTLER, Robin

SCOTT, Ian, C

VOUSDEN, Katherine, A


STRAIN, Martin, D

CARMEN, Sara

ENGLAND, Elizabeth, H

KEMP, Benjamin, P

REES, David, G


OVERED-SAYER, Catherine

SLEEMAN, Matthew

HOUSLAY, Kirsty


CHRISTOPHER WINTER for MedImmune Limited

THE SCHEDULE

APPLICATIONS					
MedImmune Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date	
IL33-105-AU-PCT	Australia	PCT	2016239331	30 Mar 2016	
IL33-105-BR-PCT	Brazil	PCT	BR112017020955-1	30 Mar 2016	
IL33-105-CA-PCT	Canada	PCT	2982400	30 Mar 2016	
IL33-105-CL-PCT	Chile	PCT	201702433	30 Mar 2016	
IL33-105-CN-PCT	China	PCT	201680019480.3	30 Mar 2016	
IL33-105-CO-PCT	Colombia	PCT	NC2017/0010753	30 Mar 2016	
IL33-105-EP-EPT	Europe	EPT	16712353.8	30 Mar 2016	
IL33-105-ID-PCT	Indonesia	PCT	P00201707610	30 Mar 2016	
IL33-105-IL-PCT	Israel	PCT	254551	30 Mar 2016	
IL33-105-IN-PCT	India	PCT	201717036395	30 Mar 2016	
IL33-105-JP-PCT	Japan	PCT	2017-551294	30 Mar 2016	
IL33-105-KR-PCT	Korea	PCT	10-2017-7030936	30 Mar 2016	
IL33-105-MX-PCT	Mexico	PCT	MX/a/2017/012616	30 Mar 2016	
IL33-105-MY-PCT	Malaysia	PCT	PI 2017703606	30 Mar 2016	
IL33-105-NZ-PCT	New Zealand	PCT	736026	30 Mar 2016	
IL33-105-RU-PCT	Russia	PCT	2017134909	30 Mar 2016	
IL33-105-SG-PCT	Singapore	PCT	11201707593U	30 Mar 2016	
IL33-105-TW-NP	Taiwan	NP	105110432	31 Mar 2016	
IL33-105-US-PCT	United States	PCT	15/562,228	30 Mar 2016	
IL33-105-WO-PCT	WO	PCT	PCT/EP2016/056973	30 Mar 2016	
IL33-105-ZA-PCT	South Africa	PCT	2017/07355	30 Mar 2016	

Priority Application:

US62/140,913 filed 31 March 2015